J&J's Janssen Announces Intent Not to Enforce Patents for Darunavir - Johnson & Johnson (NYSE:JNJ)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

J&J's (NYSE: JNJ) Janssen PharmaceuticalCompanies today announced their intention not to enforcethe patents they own and control on the antiretroviral (ARV) drug darunavirprovided the darunavir product is medically acceptable and is used only inresource-limited settings.^1 This announcement is intended to assure genericmanufacturers that they may manufacture high quality darunavir product used inSSA and the LDCs without a concern that Janssen will accuse these activitiesof infringing its darunavir patents.This new policy anticipates a greater future need to supply affordable genericversions of darunavir (brand name PREZISTA^®) for the treatment of peopleliving with HIV in the territory, and is consistent with the Company's focuson access to medicines in those countries with the highest rates of HIVinfection and economic vulnerability.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!